Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in …

VA Mensah, A Gueye, M Ndiaye, NJ Edwards… - PLoS …, 2016 - journals.plos.org
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of
control measures. If the goal of elimination is to be achieved, additional control measures …

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME …

C Ogwang, M Afolabi, D Kimani, YJ Jagne, SH Sheehy… - PloS one, 2013 - journals.plos.org
Background Heterologous prime boost immunization with chimpanzee adenovirus 63
(ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently …

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations

D Kimani, YJ Jagne, M Cox, E Kimani, CM Bliss… - Molecular Therapy, 2014 - cell.com
To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit
from both potent cellular and humoral immunity. These requirements are met by a …

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

VS Moorthy, EB Imoukhuede, P Milligan… - PLoS …, 2004 - journals.plos.org
Background Many malaria vaccines are currently in development, although very few have
been evaluated for efficacy in the field. Plasmodium falciparum multiple epitope (ME) …

Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants

MO Afolabi, AB Tiono, UJ Adetifa, JB Yaro… - Molecular Therapy, 2016 - cell.com
Malaria remains a significant global health burden and a vaccine would make a substantial
contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara …

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara …

T Rampling, KJ Ewer, G Bowyer… - The Journal of …, 2016 - academic.oup.com
Background. The need for a highly efficacious vaccine against Plasmodium falciparum
remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the …

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

AB Tiono, I Nébié, N Anagnostou, AS Coulibaly… - PloS one, 2018 - journals.plos.org
Background Heterologous prime boost immunization with chimpanzee adenovirus 63
(ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy …

Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in Gambian infants and neonates: a …

VA Mensah, S Roetynck, EK Kanteh, G Bowyer… - Frontiers in …, 2017 - frontiersin.org
Background Heterologous prime-boost vaccination with chimpanzee adenovirus 63
(ChAd63) and modified vaccinia virus Ankara (MVA) encoding multiple epitope string …

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum …

C Ogwang, D Kimani, NJ Edwards, R Roberts… - Science translational …, 2015 - science.org
Protective immunity to the liver stage of the malaria parasite can be conferred by vaccine-
induced T cells, but no subunit vaccination approach based on cellular immunity has shown …

Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants

CM Bliss, A Drammeh, G Bowyer, GS Sanou… - Molecular Therapy, 2017 - cell.com
Heterologous prime-boosting with viral vectors encoding the pre-erythrocytic antigen
thrombospondin-related adhesion protein fused to a multiple epitope string (ME-TRAP) …